Arne Schneuing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arne Schneuing has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Bruno Emmanuel Correia
Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
8 shared publications Michael Bronstein
University of Oxford
5 shared publicationsMax Welling
Microsoft Research AI4Science, Amsterdam, Netherlands
3 shared publications- Michael M. Bronstein
Department of Computer Science, University of Oxford, Oxford, UK; AITHYRA, Research Institute for Biomedical Artificial Intelligence, Austrian Academy of Sciences, Vienna, Austria
3 shared publications - Philippe Schwaller
École Polytechnique Fédérale de Lausanne
3 shared publications - Rebecca Manuela Neeser
École Polytechnique Fédérale de Lausanne
3 shared publications
Latest Publications
- Open Access
- 14 May 2026
- Published by IOP Publishing in Machine Learning: Science and Technology
- Vol. 7 (3) , 035015
Flow-based fragment identification via binding site-specific latent representations
Fragment-based drug design is a promising strategy leveraging the binding of small chemical moieties that can efficiently guide drug discovery. The initial step of fragment identification remains challenging, as fragments often bind weakly and non-specifically. We developed a protein-fragment encoder that relies on a contrastive learning approach to map both molecular fragments and protein surfaces in a shared latent space. The encoder captures interaction-relevant features and achieves strong discrimination between binding and non-binding regions, reaching ROC–area under the curve values of 0.92 on pocket surfaces and enrichment factors of 22.85 across full protein surfaces. Building on this representation, our generative method LatentFrag produces chemically realistic fragment identities and positions conditioned on the protein surface. LatentFrag improves fragment recovery over docking-based virtual screening, achieving a sampling hit rate more than four times higher at a fraction of its computational cost providing a valuable starting point for fragment hit discovery. We further show the practical utility of LatentFrag and extend the workflow to full ligand design tasks. Together, these approaches contribute to advancing fragment identification and provide valuable tools for fragment-based drug discovery.
- 14 May 2026
- Published by IOP Publishing in Machine Learning: Science and Technology
- Vol. 7 (3) , 035015
Open AccessFlow-based fragment identification via binding site-specific latent representations
Fragment-based drug design is a promising strategy leveraging the binding of small chemical moieties that can efficiently guide drug discovery. The initial step of fragment identification remains challenging, as fragments often bind weakly and non-specifically. We developed a protein-fragment encoder that relies on a contrastive learning approach to map both molecular fragments and protein surfaces in a shared latent space. The encoder captures interaction-relevant features and achieves strong discrimination between binding and non-binding regions, reaching ROC–area under the curve values of 0.92 on pocket surfaces and enrichment factors of 22.85 across full protein surfaces. Building on this representation, our generative method LatentFrag produces chemically realistic fragment identities and positions conditioned on the protein surface. LatentFrag improves fragment recovery over docking-based virtual screening, achieving a sampling hit rate more than four times higher at a fraction of its computational cost providing a valuable starting point for fragment hit discovery. We further show the practical utility of LatentFrag and extend the workflow to full ligand design tasks. Together, these approaches contribute to advancing fragment identification and provide valuable tools for fragment-based drug discovery.
- Open Access
Multi-domain Distribution Learning for De Novo Drug Design
We introduce DrugFlow, a generative model for structure-based drug design that integrates continuous flow matching with discrete Markov bridges, demonstrating state-of-the-art performance in learning chemical, geometric, and physical aspects of three-dimensional protein-ligand data. We endow DrugFlow with an uncertainty estimate that is able to detect out-of-distribution samples. To further enhance the sampling process towards distribution regions with desirable metric values, we propose a joint preference alignment scheme applicable to both flow matching and Markov bridge frameworks. Furthermore, we extend our model to also explore the conformational landscape of the protein by jointly sampling side chain angles and molecules.
Open AccessMulti-domain Distribution Learning for De Novo Drug Design
We introduce DrugFlow, a generative model for structure-based drug design that integrates continuous flow matching with discrete Markov bridges, demonstrating state-of-the-art performance in learning chemical, geometric, and physical aspects of three-dimensional protein-ligand data. We endow DrugFlow with an uncertainty estimate that is able to detect out-of-distribution samples. To further enhance the sampling process towards distribution regions with desirable metric values, we propose a joint preference alignment scheme applicable to both flow matching and Markov bridge frameworks. Furthermore, we extend our model to also explore the conformational landscape of the protein by jointly sampling side chain angles and molecules.
- Top Cited Papers
- 14 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6761) , eadv9817
Scalable emulation of protein equilibrium ensembles with generative deep learning
Following the sequence and structure revolutions, predicting functionally relevant protein structure changes at scale remains an outstanding challenge. We introduce BioEmu, a deep learning system that emulates protein equilibrium ensembles by generating thousands of statistically independent structures per hour on a single graphics processing unit (GPU). BioEmu integrates more than 200 milliseconds of molecular dynamics (MD) simulations, static structures, and experimental protein stabilities using new training algorithms. It captures diverse functional motions—including cryptic pocket formation, local unfolding, and domain rearrangements—and predicts relative free energies with 1 kilocalorie per mole accuracy compared with millisecond-scale MD and experimental data. BioEmu provides mechanistic insights by jointly modeling structural ensembles and thermodynamic properties. This approach amortizes the cost of MD and experimental data generation, demonstrating a scalable path toward understanding and designing protein function.
- 14 August 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 389 (6761) , eadv9817
Top Cited PapersScalable emulation of protein equilibrium ensembles with generative deep learning
Following the sequence and structure revolutions, predicting functionally relevant protein structure changes at scale remains an outstanding challenge. We introduce BioEmu, a deep learning system that emulates protein equilibrium ensembles by generating thousands of statistically independent structures per hour on a single graphics processing unit (GPU). BioEmu integrates more than 200 milliseconds of molecular dynamics (MD) simulations, static structures, and experimental protein stabilities using new training algorithms. It captures diverse functional motions—including cryptic pocket formation, local unfolding, and domain rearrangements—and predicts relative free energies with 1 kilocalorie per mole accuracy compared with millisecond-scale MD and experimental data. BioEmu provides mechanistic insights by jointly modeling structural ensembles and thermodynamic properties. This approach amortizes the cost of MD and experimental data generation, demonstrating a scalable path toward understanding and designing protein function.
- Top Cited PapersOpen Access
- 15 January 2025
- Published by Springer Nature in Nature
- Vol. 639 (8054) , 522-531
Targeting protein–ligand neosurfaces with a generalizable deep learning tool
Molecular recognition events between proteins drive biological processes in living systems1. However, higher levels of mechanistic regulation have emerged, in which protein–protein interactions are conditioned to small molecules2,3,4,5. Despite recent advances, computational tools for the design of new chemically induced protein interactions have remained a challenging task for the field6,7. Here we present a computational strategy for the design of proteins that target neosurfaces, that is, surfaces arising from protein–ligand complexes. To develop this strategy, we leveraged a geometric deep learning approach based on learned molecular surface representations8,9 and experimentally validated binders against three drug-bound protein complexes: Bcl2–venetoclax, DB3–progesterone and PDF1–actinonin. All binders demonstrated high affinities and accurate specificities, as assessed by mutational and structural characterization. Remarkably, surface fingerprints previously trained only on proteins could be applied to neosurfaces induced by interactions with small molecules, providing a powerful demonstration of generalizability that is uncommon in other deep learning approaches. We anticipate that such designed chemically induced protein interactions will have the potential to expand the sensing repertoire and the assembly of new synthetic pathways in engineered cells for innovative drug-controlled cell-based therapies10.
- 15 January 2025
- Published by Springer Nature in Nature
- Vol. 639 (8054) , 522-531
Top Cited PapersOpen AccessTargeting protein–ligand neosurfaces with a generalizable deep learning tool
Molecular recognition events between proteins drive biological processes in living systems1. However, higher levels of mechanistic regulation have emerged, in which protein–protein interactions are conditioned to small molecules2,3,4,5. Despite recent advances, computational tools for the design of new chemically induced protein interactions have remained a challenging task for the field6,7. Here we present a computational strategy for the design of proteins that target neosurfaces, that is, surfaces arising from protein–ligand complexes. To develop this strategy, we leveraged a geometric deep learning approach based on learned molecular surface representations8,9 and experimentally validated binders against three drug-bound protein complexes: Bcl2–venetoclax, DB3–progesterone and PDF1–actinonin. All binders demonstrated high affinities and accurate specificities, as assessed by mutational and structural characterization. Remarkably, surface fingerprints previously trained only on proteins could be applied to neosurfaces induced by interactions with small molecules, providing a powerful demonstration of generalizability that is uncommon in other deep learning approaches. We anticipate that such designed chemically induced protein interactions will have the potential to expand the sensing repertoire and the assembly of new synthetic pathways in engineered cells for innovative drug-controlled cell-based therapies10.
- Top Cited PapersOpen Access
- 9 December 2024
- Published by Springer Nature in Nature Computational Science
- Vol. 4 (12) , 899-909
Structure-based drug design with equivariant diffusion models
Structure-based drug design (SBDD) aims to design small-molecule ligands that bind with high affinity and specificity to pre-determined protein targets. Generative SBDD methods leverage structural data of drugs with their protein targets to propose new drug candidates. However, most existing methods focus exclusively on bottom-up de novo design of compounds or tackle other drug development challenges with task-specific models. The latter requires curation of suitable datasets, careful engineering of the models and retraining from scratch for each task. Here we show how a single pretrained diffusion model can be applied to a broader range of problems, such as off-the-shelf property optimization, explicit negative design and partial molecular design with inpainting. We formulate SBDD as a three-dimensional conditional generation problem and present DiffSBDD, an SE(3)-equivariant diffusion model that generates novel ligands conditioned on protein pockets. Furthermore, we show how additional constraints can be used to improve the generated drug candidates according to a variety of computational metrics.
- 9 December 2024
- Published by Springer Nature in Nature Computational Science
- Vol. 4 (12) , 899-909
Top Cited PapersOpen AccessStructure-based drug design with equivariant diffusion models
Structure-based drug design (SBDD) aims to design small-molecule ligands that bind with high affinity and specificity to pre-determined protein targets. Generative SBDD methods leverage structural data of drugs with their protein targets to propose new drug candidates. However, most existing methods focus exclusively on bottom-up de novo design of compounds or tackle other drug development challenges with task-specific models. The latter requires curation of suitable datasets, careful engineering of the models and retraining from scratch for each task. Here we show how a single pretrained diffusion model can be applied to a broader range of problems, such as off-the-shelf property optimization, explicit negative design and partial molecular design with inpainting. We formulate SBDD as a three-dimensional conditional generation problem and present DiffSBDD, an SE(3)-equivariant diffusion model that generates novel ligands conditioned on protein pockets. Furthermore, we show how additional constraints can be used to improve the generated drug candidates according to a variety of computational metrics.
- Open Access
Scalable emulation of protein equilibrium ensembles with generative deep learning
Following the sequence and structure revolutions, predicting the dynamical mechanisms of proteins that implement biological function remains an outstanding scientific challenge. Several experimental techniques and molecular dynamics (MD) simulations can, in principle, determine conformational states, binding configurations and their probabilities, but suffer from low throughput. Here we develop a Biomolecular Emulator (BioEmu), a generative deep learning system that can generate thousands of statistically independent samples from the protein structure ensemble per hour on a single graphics processing unit. By leveraging novel training methods and vast data of protein structures, over 200 milliseconds of MD simulation, and experimental protein stabilities, BioEmu's protein ensembles represent equilibrium in a range of challenging and practically relevant metrics. Qualitatively, BioEmu samples many functionally relevant conformational changes, ranging from formation of cryptic pockets, over unfolding of specific protein regions, to large-scale domain rearrangements. Quantitatively, BioEmu samples protein conformations with relative free energy errors around 1 kcal/mol, as validated against millisecond-timescale MD simulation and experimentally-measured protein stabilities. By simultaneously emulating structural ensembles and thermodynamic properties, BioEmu reveals mechanistic insights, such as the causes for fold destabilization of mutants, and can efficiently provide experimentally-testable hypotheses.
Open AccessScalable emulation of protein equilibrium ensembles with generative deep learning
Following the sequence and structure revolutions, predicting the dynamical mechanisms of proteins that implement biological function remains an outstanding scientific challenge. Several experimental techniques and molecular dynamics (MD) simulations can, in principle, determine conformational states, binding configurations and their probabilities, but suffer from low throughput. Here we develop a Biomolecular Emulator (BioEmu), a generative deep learning system that can generate thousands of statistically independent samples from the protein structure ensemble per hour on a single graphics processing unit. By leveraging novel training methods and vast data of protein structures, over 200 milliseconds of MD simulation, and experimental protein stabilities, BioEmu's protein ensembles represent equilibrium in a range of challenging and practically relevant metrics. Qualitatively, BioEmu samples many functionally relevant conformational changes, ranging from formation of cryptic pockets, over unfolding of specific protein regions, to large-scale domain rearrangements. Quantitatively, BioEmu samples protein conformations with relative free energy errors around 1 kcal/mol, as validated against millisecond-timescale MD simulation and experimentally-measured protein stabilities. By simultaneously emulating structural ensembles and thermodynamic properties, BioEmu reveals mechanistic insights, such as the causes for fold destabilization of mutants, and can efficiently provide experimentally-testable hypotheses.
- Top Cited PapersOpen Access
- 11 April 2024
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 6 (4) , 417-427
Equivariant 3D-conditional diffusion model for molecular linker design
Fragment-based drug discovery has been an effective paradigm in early-stage drug development. An open challenge in this area is designing linkers between disconnected molecular fragments of interest to obtain chemically relevant candidate drug molecules. In this work, we propose DiffLinker, an E(3)-equivariant three-dimensional conditional diffusion model for molecular linker design. Given a set of disconnected fragments, our model places missing atoms in between and designs a molecule incorporating all the initial fragments. Unlike previous approaches that are only able to connect pairs of molecular fragments, our method can link an arbitrary number of fragments. Additionally, the model automatically determines the number of atoms in the linker and its attachment points to the input fragments. We demonstrate that DiffLinker outperforms other methods on the standard datasets, generating more diverse and synthetically accessible molecules. We experimentally test our method in real-world applications, showing that it can successfully generate valid linkers conditioned on target protein pockets.
- 11 April 2024
- Published by Springer Nature in Nature Machine Intelligence
- Vol. 6 (4) , 417-427
Top Cited PapersOpen AccessEquivariant 3D-conditional diffusion model for molecular linker design
Fragment-based drug discovery has been an effective paradigm in early-stage drug development. An open challenge in this area is designing linkers between disconnected molecular fragments of interest to obtain chemically relevant candidate drug molecules. In this work, we propose DiffLinker, an E(3)-equivariant three-dimensional conditional diffusion model for molecular linker design. Given a set of disconnected fragments, our model places missing atoms in between and designs a molecule incorporating all the initial fragments. Unlike previous approaches that are only able to connect pairs of molecular fragments, our method can link an arbitrary number of fragments. Additionally, the model automatically determines the number of atoms in the linker and its attachment points to the input fragments. We demonstrate that DiffLinker outperforms other methods on the standard datasets, generating more diverse and synthetically accessible molecules. We experimentally test our method in real-world applications, showing that it can successfully generate valid linkers conditioned on target protein pockets.
- Open Access
Targeting protein-ligand neosurfaces using a generalizable deep learning approach
Molecular recognition events between proteins drive biological processes in living systems. However, higher levels of mechanistic regulation have emerged, where protein-protein interactions are conditioned to small molecules. Here, we present a computational strategy for the design of proteins that target neosurfaces, i.e. surfaces arising from protein-ligand complexes. To do so, we leveraged a deep learning approach based on learned molecular surface representations and experimentally validated binders against three drug-bound protein complexes. Remarkably, surface fingerprints trained only on proteins can be applied to neosurfaces emerging from small molecules, serving as a powerful demonstration of generalizability that is uncommon in deep learning approaches. The designed chemically-induced protein interactions hold the potential to expand the sensing repertoire and the assembly of new synthetic pathways in engineered cells.
Open AccessTargeting protein-ligand neosurfaces using a generalizable deep learning approach
Molecular recognition events between proteins drive biological processes in living systems. However, higher levels of mechanistic regulation have emerged, where protein-protein interactions are conditioned to small molecules. Here, we present a computational strategy for the design of proteins that target neosurfaces, i.e. surfaces arising from protein-ligand complexes. To do so, we leveraged a deep learning approach based on learned molecular surface representations and experimentally validated binders against three drug-bound protein complexes. Remarkably, surface fingerprints trained only on proteins can be applied to neosurfaces emerging from small molecules, serving as a powerful demonstration of generalizability that is uncommon in deep learning approaches. The designed chemically-induced protein interactions hold the potential to expand the sensing repertoire and the assembly of new synthetic pathways in engineered cells.
- Open Access
RetroBridge: Modeling Retrosynthesis with Markov Bridges
Retrosynthesis planning is a fundamental challenge in chemistry which aims at designing reaction pathways from commercially available starting materials to a target molecule. Each step in multi-step retrosynthesis planning requires accurate prediction of possible precursor molecules given the target molecule and confidence estimates to guide heuristic search algorithms. We model single-step retrosynthesis planning as a distribution learning problem in a discrete state space. First, we introduce the Markov Bridge Model, a generative framework aimed to approximate the dependency between two intractable discrete distributions accessible via a finite sample of coupled data points. Our framework is based on the concept of a Markov bridge, a Markov process pinned at its endpoints. Unlike diffusion-based methods, our Markov Bridge Model does not need a tractable noise distribution as a sampling proxy and directly operates on the input product molecules as samples from the intractable prior distribution. We then address the retrosynthesis planning problem with our novel framework and introduce RetroBridge, a template-free retrosynthesis modeling approach that achieves state-of-the-art results on standard evaluation benchmarks.
Open AccessRetroBridge: Modeling Retrosynthesis with Markov Bridges
Retrosynthesis planning is a fundamental challenge in chemistry which aims at designing reaction pathways from commercially available starting materials to a target molecule. Each step in multi-step retrosynthesis planning requires accurate prediction of possible precursor molecules given the target molecule and confidence estimates to guide heuristic search algorithms. We model single-step retrosynthesis planning as a distribution learning problem in a discrete state space. First, we introduce the Markov Bridge Model, a generative framework aimed to approximate the dependency between two intractable discrete distributions accessible via a finite sample of coupled data points. Our framework is based on the concept of a Markov bridge, a Markov process pinned at its endpoints. Unlike diffusion-based methods, our Markov Bridge Model does not need a tractable noise distribution as a sampling proxy and directly operates on the input product molecules as samples from the intractable prior distribution. We then address the retrosynthesis planning problem with our novel framework and introduce RetroBridge, a template-free retrosynthesis modeling approach that achieves state-of-the-art results on standard evaluation benchmarks.
- Open Access
Structure-based Drug Design with Equivariant Diffusion Models
Structure-based drug design (SBDD) aims to design small-molecule ligands that bind with high affinity and specificity to pre-determined protein targets. In this paper, we formulate SBDD as a 3D-conditional generation problem and present DiffSBDD, an SE(3)-equivariant 3D-conditional diffusion model that generates novel ligands conditioned on protein pockets. Comprehensive in silico experiments demonstrate the efficiency and effectiveness of DiffSBDD in generating novel and diverse drug-like ligands with competitive docking scores. We further explore the flexibility of the diffusion framework for a broader range of tasks in drug design campaigns, such as off-the-shelf property optimization and partial molecular design with inpainting.
Open AccessStructure-based Drug Design with Equivariant Diffusion Models
Structure-based drug design (SBDD) aims to design small-molecule ligands that bind with high affinity and specificity to pre-determined protein targets. In this paper, we formulate SBDD as a 3D-conditional generation problem and present DiffSBDD, an SE(3)-equivariant 3D-conditional diffusion model that generates novel ligands conditioned on protein pockets. Comprehensive in silico experiments demonstrate the efficiency and effectiveness of DiffSBDD in generating novel and diverse drug-like ligands with competitive docking scores. We further explore the flexibility of the diffusion framework for a broader range of tasks in drug design campaigns, such as off-the-shelf property optimization and partial molecular design with inpainting.